Page 66 - ARNM-1-1

Advances in Radiotherapy
& Nuclear Medicine PRaG therapy for renal pelvis carcinoma

the subject construction support project of the Second 4. Vanpouille-Box C, Pilones KA, Wennerberg E, et al., 2015,
Affiliated Hospital of Soochow University (the Talent In situ vaccination by radiotherapy to improve responses to
Support Project of the Academy of Science and Education) anti-CTLA-4 treatment. Vaccine, 33: 7415–7422.
(No. XKTJ-RC2012015), and the Open Program of https://doi.org/10.1016/j.vaccine.2015.05.105
NHC Key Laboratory of Nuclear Medicine and Jiangsu
Key Laboratory of Molecular Nuclear Medicine (No. 5. Bernstein MB, Krishnan S, Hodge JW, et al., 2016,
Immunotherapy and stereotactic ablative radiotherapy
KF202205). (ISABR): A curative approach? Nat Rev Clin Oncol, 13: 516–
Conflict of interest 524.
https://doi.org/10.1038/nrclinonc.2016.30
The authors declare they have no competing interests.
6. Birtle A, Johnson M, Chester J, et al., 2020, Adjuvant
Author contributions chemotherapy in upper tract urothelial carcinoma (the
POUT trial): A phase 3, open-label, randomised controlled
Conceptualization: Zhihui Hong trial. Lancet, 395: 1268–1277.
Investigation: Yuehong Kong, Meiling Xu, Yifu Ma
Writing – original draft: Zhihui Hong, Hong Xu https://doi.org/10.1016/S0140-6736(20)30415-3
Writing – review & editing: Liyuan Zhang, Pengfei Xing 7. Roupret M, Babjuk M, Burger M, et al., 2021, European
association of urology guidelines on upper urinary tract
Ethics approval and consent to participate urothelial carcinoma: 2020 update. Eur Urol, 79: 62–79.

This study involved a human participant and was https://doi.org/10.1016/j.eururo.2020.05.042
reviewed and approved by the Ethics Committee of the 8. Witjes JA, Bruins HM, Cathomas R, et al., 2021, European
Second Affiliated Hospital of Soochow University. The association of urology guidelines on muscle-invasive and
patient/participant provided written informed consent to metastatic bladder cancer: Summary of the 2020 guidelines.
participate in this study. Eur Urol, 79: 82–104.
Consent for publication https://doi.org/10.1016/j.eururo.2020.03.055

Written informed consent was obtained from the individual 9. Fujita K, Yamamoto Y, Kanai O, et al., 2020, Retreatment
with anti-PD-1 antibody in non-small cell lung cancer
for the publication of any potentially identifiable images or patients previously treated with anti-PD-L1 antibody.
data included in this article.
Thorac Cancer, 11: 15–18.
Availability of data https://doi.org/10.1111/1759-7714.13241

The original contributions presented in the study are 10. Martini DJ, Lalani AA, Bosse D, et al., 2017, Response to
included in the article/supplementary material. Further single agent PD-1 inhibitor after progression on previous
inquiries can be directed to the corresponding authors. PD-1/PD-L1 inhibitors: A case series. J Immunother Cancer,
5: 66.
References https://doi.org/10.1186/s40425-017-0273-y

1. Wu Y, Mou H, 2020, Complete remission in a patient with 11. Fujita K, Uchida N, Yamamoto Y, et al., 2019, Retreatment
advanced renal pelvis carcinoma with lung metastasis with anti-PD-L1 antibody in advanced non-small cell
treated with durvalumab immunotherapy: A case report. lung cancer previously treated with anti-PD-1 antibodies.
Ann Palliat Med, 9: 2408–2413. Anticancer Res, 39: 3917–3921.
https://doi.org/10.21037/apm-20-1338 https://doi.org/10.21873/anticanres.13543
2. Farina MS, Lundgren KT, Bellmunt J, 2017, Immunotherapy 12. Fujita K, Uchida N, Kanai O, et al., 2018, Retreatment with
in urothelial cancer: Recent results and future perspectives. pembrolizumab in advanced non-small cell lung cancer
Drugs, 77: 1077–1089. patients previously treated with nivolumab: Emerging
https://doi.org/10.1007/s40265-017-0748-7 reports of 12 cases. Cancer Chemother Pharmacol, 81: 1105–
1109.
3. Lan J, Li R, Yin LM, et al., 2018, Targeting myeloid-derived
suppressor cells and programmed death ligand 1 confers https://doi.org/10.1007/s00280-018-3585-9
therapeutic advantage of ablative hypofractionated radiation 13. Hakozaki T, Okuma Y, Kashima J, 2018, Re-challenging
therapy compared with conventional fractionated radiation immune checkpoint inhibitor in a patient with advanced
therapy. Int J Radiat Oncol Biol Phys, 101: 74–87. non-small cell lung cancer: A case report. BMC Cancer,
https://doi.org/10.1016/j.ijrobp.2018.01.071 18: 302.

Volume 1 Issue 1 (2023) 6 https://doi.org/10.36922/arnm.0441